



The EarlyCDT™-Lung, a Blood Test Which Aids in Lung Cancer Risk Assessment and Diagnosis, Reaches Two Year Anniversary of Commercial Release Date

The EarlyCDT-Lung test, a revolutionary lung cancer risk assessment and detection test, reaches two years anniversary of commercial availability in the United States.

De Soto, KS ([PRWEB](#)) June 08, 2011 -- The [EarlyCDT-Lung Test](#), an early detection blood test used to help assess [lung cancer risk](#) and aid in diagnosing the disease, reached the two year anniversary of its commercial release on May 18. In a matter of two short years, EarlyCDT-Lung has been ordered by hundreds of physicians and aided in the detection of multiple early stage lung cancers.

A simple blood test, EarlyCDT-Lung was designed to assist in [lung cancer risk](#) assessment and detection, in the earliest stages of the disease. According to the American Cancer Society, survival rates are much higher when cancer is diagnosed early. Because lung cancer is often found symptomatically, most cases are discovered after the disease has spread. In these cases, the 5-year survival rate is only 15%. By testing patients who are at a high risk for developing lung cancer, before symptoms appear, EarlyCDT-Lung is helping physicians [diagnose lung cancer](#) sooner, when treatment options are more likely to be successful.

The EarlyCDT-Lung test detects a patient's immune response to antigens produced by solid-tumor cells, in the form of autoantibodies. Because these autoantibodies are not produced by healthy individuals at higher levels, the EarlyCDT-Lung test enables physicians to identify those patients who are at an increased lung cancer risk or in the early [stages of lung cancer](#).

Developed and made available by Oncimmune®, EarlyCDT-Lung is beginning to change the way medical professionals approach lung cancer diagnosis. Oncimmune is a certified laboratory committed to the advancement of early cancer detection through proprietary autoantibody assay technologies; technology which was initially identified by John Robertson, M.D., chief scientific officer of Oncimmune LTD and professor of surgery at Nottingham University, England.

Released commercially on May 18, 2009, EarlyCDT-Lung has since been used by hundreds of doctors for lung cancer risk assessments and the detection of multiple early stage lung cancers. In two short years researchers at Oncimmune have analyzed thousands of samples; with sample intake rising more than 300% when comparing January 2011 with April 2011.

“We are encouraged by the results we have seen since the commercial launch of the EarlyCDT-Lung test,” said Greg Stanley of Oncimmune. “At Oncimmune we’re dedicated to the advancement of lung cancer detection through autoantibody assay technology and the EarlyCDT-Lung test is helping us reach our goals.”

Results of the initial commercial launch will be presented at the World Congress for Lung Cancer in Amsterdam in July. Additionally, EarlyCDT-Lung is scheduled to launch commercially in the United Kingdom later this year. Look for these and other exciting developments from Oncimmune as they continue to develop new and innovate methods to identify and diagnosis cancer in its earliest stages. For more information on the EarlyCDT-Lung test and other autoantibody assay research, visit www.hellohaveyouheard.com.

ABOUT ONCIMMUNE



Oncimmune (USA) LLC, founded in 2006, is an industry leader in early cancer detection. Oncimmune (USA) LLC is a wholly-owned subsidiary of Oncimmune LTD based in Nottingham, England. The company is committed to advancing early cancer detection through proprietary autoantibody assay technologies based upon biological technology initially identified by John Robertson, M.D., professor of surgery at Nottingham University, England, and Chief Scientific Officer of Oncimmune LTD. Ongoing research and development is conducted by Oncimmune under the direction of Dr. Robertson. The company's mission is to develop early cancer detection tests to identify more than 90 percent of solid-tumor cancers, which make up 70 percent of all cancers including lung, breast, colorectal, prostate, stomach, pancreatic and ovarian. Oncimmune's metro Kansas City laboratory is CLIA-certified under the Clinical Laboratory Improvements Amendment of 1988. Oncimmune LTD owns a portfolio of patents including No. 7,402,403 and No. 7,205,117.

###



Contact Information

Greg Stanley

Oncimmune

<http://www.hellohaveyouheard.com/>

(317) 863-2921

Online Web 2.0 Version

You can read the online version of this press release [here](#).